Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Shuichi OtaToshihiro MatsukawaSatoshi YamamotoShinichi ItoMotohiro ShindoKazuya SatoTakeshi KondoKyuhei KohdaHajime SakaiAkio MoriTohru TakahashiHiroshi IkedaHiroyuki KurodaYoshihito HaseyamaMasaki YamamotoTakeo SarashinaMakoto YoshidaRyoji KobayashiMitsufumi NishioToshimichi IshiharaYasuo HirayamaYasutaka KakinokiHajime KobayashiTakashi FukuharaMasahiro ImamuraMitsutoshi KurosawaPublished in: European journal of haematology (2018)
Although long-term outcomes were similar in CML-CP patients treated with each TKI regardless of first-line TKI selection, severe AEs in first-line TKI therapy decreased their survival rates. Early change in TKIs is recommended, when faced with severe AEs of specific TKIs.